FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317207980> ?p ?o ?g. }

• W4317207980 endingPage "6066" @default.
• W4317207980 startingPage "6059" @default.
• W4317207980 abstract "No standard of care therapy exists for patients with metastatic uveal melanoma who are not HLA-A2:01 positive. The phase 1b, open-label CLEVER study (NCT03408587) evaluated V937 in combination with ipilimumab in patients with uveal melanoma.Adults with advanced uveal melanoma and liver metastases received up to 8 cycles of intravenous V937 (1 × 109 TCID50 per infusion; infusions on days 1, 3, 5, and 8 [cycle 1], then every 3 weeks [Q3W] thereafter [cycles 2-8]) and 4 cycles of intravenous ipilimumab 3 mg/kg Q3W (beginning at cycle 1 day 8). The primary endpoint was safety. Secondary endpoints included objective response rate and progression-free survival (PFS) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).Eleven patients were enrolled (median age, 65.0 years) and received a median of 6 injections of V937 and 3.5 infusions of ipilimumab. The best overall response was stable disease in 3 patients and progressive disease in 8 patients. All patients exhibited progression per irRECIST, with a 9% irPFS rate at week 26. Ten patients had treatment-related AEs, the most frequent of which were diarrhea (55%), fatigue (45%), and myalgia (36%). Two grade 3 AEs (diarrhea, n = 2) were considered related to ipilimumab; neither was related to V937.Although the combination of V937 with ipilimumab had a manageable safety profile, meaningful clinical benefit was not observed in patients with uveal melanoma and liver metastases.ClinicalTrials.gov, NCT03408587 (January 24, 2018)." @default.
• W4317207980 created "2023-01-18" @default.
• W4317207980 creator A5008479799 @default.
• W4317207980 creator A5044615683 @default.
• W4317207980 creator A5046118383 @default.
• W4317207980 creator A5046320640 @default.
• W4317207980 creator A5088007604 @default.
• W4317207980 creator A5091053901 @default.
• W4317207980 date "2023-01-18" @default.
• W4317207980 modified "2023-10-14" @default.
• W4317207980 title "Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma" @default.
• W4317207980 cites W1545177819 @default.
• W4317207980 cites W1823057065 @default.
• W4317207980 cites W1907114983 @default.
• W4317207980 cites W1913328895 @default.
• W4317207980 cites W1971890973 @default.
• W4317207980 cites W2005576578 @default.
• W4317207980 cites W2038434969 @default.
• W4317207980 cites W2055835855 @default.
• W4317207980 cites W2069681076 @default.
• W4317207980 cites W2081863398 @default.
• W4317207980 cites W2092055002 @default.
• W4317207980 cites W2104885590 @default.
• W4317207980 cites W2109274792 @default.
• W4317207980 cites W2136443494 @default.
• W4317207980 cites W2167255026 @default.
• W4317207980 cites W2217683734 @default.
• W4317207980 cites W2263896208 @default.
• W4317207980 cites W2300492004 @default.
• W4317207980 cites W2515516401 @default.
• W4317207980 cites W2516337088 @default.
• W4317207980 cites W2565059842 @default.
• W4317207980 cites W2740583382 @default.
• W4317207980 cites W2946205311 @default.
• W4317207980 cites W2949122086 @default.
• W4317207980 cites W2976929154 @default.
• W4317207980 cites W3003495448 @default.
• W4317207980 cites W3038039573 @default.
• W4317207980 cites W3049037119 @default.
• W4317207980 cites W3096267580 @default.
• W4317207980 cites W3161871080 @default.
• W4317207980 cites W3200574709 @default.
• W4317207980 cites W3211945524 @default.
• W4317207980 cites W4226109861 @default.
• W4317207980 cites W4312105938 @default.
• W4317207980 doi "https://doi.org/10.1007/s00432-022-04510-3" @default.
• W4317207980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36651961" @default.
• W4317207980 hasPublicationYear "2023" @default.
• W4317207980 type Work @default.
• W4317207980 citedByCount "0" @default.
• W4317207980 crossrefType "journal-article" @default.
• W4317207980 hasAuthorship W4317207980A5008479799 @default.
• W4317207980 hasAuthorship W4317207980A5044615683 @default.
• W4317207980 hasAuthorship W4317207980A5046118383 @default.
• W4317207980 hasAuthorship W4317207980A5046320640 @default.
• W4317207980 hasAuthorship W4317207980A5088007604 @default.
• W4317207980 hasAuthorship W4317207980A5091053901 @default.
• W4317207980 hasBestOaLocation W43172079801 @default.
• W4317207980 hasConcept C121608353 @default.
• W4317207980 hasConcept C126322002 @default.
• W4317207980 hasConcept C141071460 @default.
• W4317207980 hasConcept C143998085 @default.
• W4317207980 hasConcept C203092338 @default.
• W4317207980 hasConcept C2775832928 @default.
• W4317207980 hasConcept C2777658100 @default.
• W4317207980 hasConcept C2777701055 @default.
• W4317207980 hasConcept C2779802037 @default.
• W4317207980 hasConcept C2780057760 @default.
• W4317207980 hasConcept C2781433595 @default.
• W4317207980 hasConcept C502942594 @default.
• W4317207980 hasConcept C535046627 @default.
• W4317207980 hasConcept C71924100 @default.
• W4317207980 hasConcept C90924648 @default.
• W4317207980 hasConceptScore W4317207980C121608353 @default.
• W4317207980 hasConceptScore W4317207980C126322002 @default.
• W4317207980 hasConceptScore W4317207980C141071460 @default.
• W4317207980 hasConceptScore W4317207980C143998085 @default.
• W4317207980 hasConceptScore W4317207980C203092338 @default.
• W4317207980 hasConceptScore W4317207980C2775832928 @default.
• W4317207980 hasConceptScore W4317207980C2777658100 @default.
• W4317207980 hasConceptScore W4317207980C2777701055 @default.
• W4317207980 hasConceptScore W4317207980C2779802037 @default.
• W4317207980 hasConceptScore W4317207980C2780057760 @default.
• W4317207980 hasConceptScore W4317207980C2781433595 @default.
• W4317207980 hasConceptScore W4317207980C502942594 @default.
• W4317207980 hasConceptScore W4317207980C535046627 @default.
• W4317207980 hasConceptScore W4317207980C71924100 @default.
• W4317207980 hasConceptScore W4317207980C90924648 @default.
• W4317207980 hasIssue "9" @default.
• W4317207980 hasLocation W43172079801 @default.
• W4317207980 hasLocation W43172079802 @default.
• W4317207980 hasOpenAccess W4317207980 @default.
• W4317207980 hasPrimaryLocation W43172079801 @default.
• W4317207980 hasRelatedWork W2155654588 @default.
• W4317207980 hasRelatedWork W2586660966 @default.
• W4317207980 hasRelatedWork W2773756552 @default.
• W4317207980 hasRelatedWork W2915045061 @default.
• W4317207980 hasRelatedWork W3185931698 @default.

• next